NCT07586995
A Post-Market Assessment of the Safety and Performance of the TriClip™ System
Recruiting
Not specifiedAges 18+ObservationalAbbott Medical Devices
~1,000 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:Tricuspid Transcatheter Edge-to-Edge Repair (TEER)
At a glance
Recruiting sites
2 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of Peri-Procedural Adverse Events
Measured over Through 30 days post-procedure
+2 more outcomes measured
Conditions
Where it's being run
5 sites across 5 statesCalifornia1
Illinois1
Texas1
Lombard1
Spain1
Study leadership
- Meghan Griffin · STUDY_DIRECTOR · Abbott
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Rate of Peri-Procedural Adverse EventsThrough 30 days post-procedure
Defined as all-cause mortality, device embolization, device thrombosis, non-elective surgery or transcatheter intervention for device- or procedure-related adverse event (AE) new pacemaker implantation and device- or procedure related major bleeding
- Tricuspid Regurgitation (TR) grade less than or equal to moderateAt 30-day follow-up
- Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score improvement of at least 10 pointsAt 30-day follow-up
All KCCQ scores are scaled from 0 (worst) to 100 (best possible status), where the higher score reflects a better health status.